Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Preventing Toxicity in Immunotherapy

Delivering Therapies to Patients Rapidly and Safely

April 25-26, 2016 | Boston, MA

PEGSummit.com/Immunotherapy

Register

SAVE up to $200!

Register by March 25

When dosed with an immunotherapy, adaptive and innate immune systems are activated, better allowing them to recognize disease cells in the body. However, the immune system also becomes more sensitive to self, potentially causing cytokine storm, macrophage activation syndrome, or autoimmunity. On Monday, April 25, at the PEGS Summit in Boston, there will be a special session devoted to Cytokine Storm: Prediction, Diagnosis, and Management which will include the below presentations. Register for a Premium Package to maximize your savings and learning opportunities while gaining access to the entire Immunotherapy Stream.

Cytokine Storm: Prediction, Diagnosis, and Management

Cytokine Storm Following CAR-T Cell Therapy: An Interdisciplinary Approach to Diagnosis and Symptom Management

Chrystal Louis, Ph.D., Co-Director, Neuroblastoma Program, Texas Children’s Hospital; Assistant Professor, Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine

Chimeric antigen receptor (CARs) positive T cells combines the specificity and anti-tumor effects of monoclonal antibodies with the direct cytotoxicity and long-term persistence of T cells. However, modifications designed to improve the affinity and anti-tumor activity of CARs increases the likelihood of on- and off-target toxicity secondary to low level antigenic expression on normal tissues. Toxicity associated with cytokine storm and macrophage activation syndrome can be life-threatening if not quickly identified and requires interdisciplinary communication and teamwork to successfully manage the symptoms.

Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

Simon Lacey, Ph.D., Director, Translational and Correlative Studies Laboratory, Product Development and Correlative Sciences, University of Pennsylvania

CAR T cells with anti-CD19 specificity have demonstrated remission rates as high as 90% in ALL patients treated with CTL019 (Maude et al., NEJM 2014), but cytokine release syndrome (CRS) can be a complication. We studied 43 cytokines, chemokines, and soluble receptors in 51 ALL patients treated with anti-CD19 CAR T cells. Biomarkers associated with severe CRS and predictive during the first 3 days after infusion of subsequent CRS4-5 compared to CRS0-3 were identified.

Managing Receptor-Engineered T Cell Cytokine Storms: Facts, Fabulations, Future Progress

Christopher A. Klebanoff, M.D., Assistant Clinical Investigator, Center for Cancer Research, National Cancer Institute

Adoptive transfer of receptor-engineered T cells targeting tumor-associated antigens can mediate durable complete responses in patients with refractory solid and hematologic malignancies. In some cases, infusion of engineered T cells is associated with a spectrum of toxicities attributed to an exuberant release of cytokines. Dissemination of this promising treatment modality beyond specialized academic medical centers will require detailed understanding of both the pathogenesis and medical management of cell-related toxicities.